Some people develop serious cardiovascular disease even though they appear to be doing everything right.
Their usual cholesterol may be treated, their blood pressure may be controlled, and they may not smoke, yet part of their risk remains unexplained.
New research suggests that an inherited blood particle called lipoprotein(a) may account for some of that hidden danger.
An analysis of more than 20,000 patients found that very high Lp(a) was associated with greater risks of stroke, cardiovascular death and major heart-related events.
The late-breaking results were presented at the 2026 scientific meeting of the Society for Cardiovascular Angiography & Interventions and the Canadian Association of Interventional Cardiology in Montreal.
Most people are familiar with LDL cholesterol. When too much LDL circulates in the blood, cholesterol can collect inside artery walls and contribute to plaque. Over time, narrowed or damaged arteries can lead to heart attacks, strokes and other cardiovascular problems.
Lp(a) looks somewhat like an LDL particle but carries an additional protein. That extra component changes how the particle behaves and may contribute to artery damage and clotting. High levels have long been recognized as an independent cardiovascular risk factor.
What makes Lp(a) unusual is that genes largely decide how much a person has. Levels are generally established early in life and remain relatively stable. Healthy eating and exercise remain important for the heart, but they usually do not dramatically lower an inherited high Lp(a) level.
This creates a problem because elevated Lp(a) is not rare. Roughly 20 percent of people are thought to have high levels. Since it causes no obvious symptoms, many may carry the risk for decades without knowing.
For the new research, investigators returned to blood samples collected during three major NIH-funded trials known as ACCORD, PEACE and SPRINT. Altogether, they analyzed plasma from 20,070 people aged at least 40. The average participant was about 65 years old.
All samples were measured using a standardized test, with Lp(a) reported in nanomoles per liter. Participants were placed into groups ranging from below 75 to at least 175 nanomoles per liter. Researchers then examined what happened to people with different levels over time.
The analysis also considered whether participants already had cardiovascular disease. This was important because the meaning of a risk marker can be different for someone who has already developed heart disease compared with someone who has never had it. The researchers adjusted their calculations for numerous health and treatment differences.
Over a median follow-up of almost four years, 1,461 participants experienced a major cardiovascular event. The researchers counted heart attacks, strokes, cardiovascular deaths and procedures used to reopen narrowed coronary arteries. Overall, about 7 percent of participants experienced one of these outcomes.
The strongest warning signal came from Lp(a) levels of 175 nanomoles per liter or higher. People at or above this level had a 31 percent higher adjusted risk of the combined cardiovascular outcome compared with the reference group. The association remained even after taking other cholesterol measurements, illnesses and treatments into account.
The individual outcomes revealed an even more interesting pattern. Very high Lp(a) was linked to a 64 percent higher risk of stroke and a 49 percent higher risk of dying from cardiovascular causes. Yet the study did not find a significant increase in heart attack risk at the same threshold.
That result may seem surprising because Lp(a) is often discussed in relation to coronary artery disease. It does not mean Lp(a) has no connection to heart attacks. Instead, this particular analysis did not detect a statistically clear increase in that outcome after other factors were considered.
People with established heart disease appeared to be especially affected. Among them, Lp(a) of at least 175 nanomoles per liter was associated with around a 30 percent higher risk of a major cardiovascular event. For people without existing cardiovascular disease, the association was weaker and statistically uncertain.
This could make Lp(a) testing particularly informative for patients who have already had cardiovascular problems. If someone has inherited high Lp(a), doctors cannot currently change their genes, but they can work more aggressively on other sources of risk. That might include lowering LDL cholesterol further, treating high blood pressure, controlling diabetes and avoiding smoking.
A major advantage of Lp(a) testing is simplicity. It can be measured with a blood test, and because levels are largely inherited and fairly stable, repeated testing may not be necessary for many people. The result can reveal information that a standard cholesterol panel does not always capture.
Still, a high result should not be treated as a prediction that a heart attack or stroke is inevitable. Cardiovascular disease develops through many interacting factors. Lp(a) is one piece of a person’s overall risk profile, not a diagnosis by itself.
The research also leaves a crucial question unanswered: if doctors directly lower Lp(a), will patients live longer or have fewer strokes and heart attacks? An observational association cannot answer that. Several medicines designed specifically to reduce Lp(a) are under investigation, and outcome trials will be needed to determine whether the biological change translates into real clinical benefit.
The study’s size is an important strength. More than 20,000 participants provided enough data to examine several Lp(a) ranges and different cardiovascular outcomes. Using stored samples from carefully conducted NIH trials also allowed researchers to connect laboratory measurements with detailed clinical information.
There are nevertheless reasons to be cautious. The three original trials were not created specifically to test Lp(a), and combining their stored samples cannot replace a trial designed around this question from the beginning. The results have also been presented at a scientific conference, so a full peer-reviewed publication will provide more detail about the methods and limitations.
Another important point is that the apparent threshold of 175 nanomoles per liter should not be interpreted as a sharp line between safe and dangerous. Cardiovascular risk generally exists on a continuum, and professional guidelines may use different thresholds depending on the clinical situation. Doctors need to interpret the number alongside the person’s broader health history.
Overall, the new findings add weight to the idea that Lp(a) can expose inherited cardiovascular risk hidden behind otherwise familiar cholesterol numbers.
The strongest associations in this analysis involved stroke and cardiovascular death, especially among people who already had heart disease. Until targeted therapies are proven, discovering high Lp(a) may be most valuable because it gives patients and doctors another reason to control every other heart risk they can.
If you care about stroke, please read studies that diets high in flavonoids could help reduce stroke risk, and MIND diet could slow down cognitive decline after stroke.
For more health information, please see recent studies about antioxidants that could help reduce the risk of dementia, and tea and coffee may help lower your risk of stroke, dementia.
Source: Society for Cardiovascular Angiography & Interventions.
